Understanding the FDA QMSR Transition: From 21 CFR 820 to ISO 13485

MISSISSAUGA, Ontario - Dec. 15, 2025 - PRLog -- The U.S. FDA's Quality Management System Regulation (QMSR) marks a major shift for medical device manufacturers. With the transition from 21 CFR Part 820 to alignment with ISO 13485:2016, organizations must rethink how they approach compliance, documentation, and audits.

To support professionals navigating this change, TalkFDA has launched an on-demand training program focused on the FDA QMSR transition. The course explains what is changing, what remains the same, and how companies can prepare without disrupting existing quality systems.

The training covers key topics such as FDA's rationale for adopting ISO 13485, structural differences between the two frameworks, impact on design controls, CAPA, risk management, supplier controls, and inspection readiness. Practical guidance is provided to help quality and regulatory teams map current processes and identify gaps early.

Designed for medical device manufacturers, quality professionals, regulatory affairs teams, auditors, and consultants, the course helps reduce uncertainty and supports a smooth transition to the new regulatory model.

The course is available as part of the TalkFDA subscription, giving learners flexible access to expert-led compliance training across quality, regulatory, and GMP topics.

About TalkFDA
TalkFDA is an online learning platform offering specialized training for pharmaceutical, medical device, and biotech professionals worldwide. The platform focuses on practical, real-world compliance education aligned with evolving global regulations.

Learn more:
https://www.talkfda.com/course/us-fda-qmsr-transition-21-cfr-820-iso-13485